For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

The American College of Lifestyle Medicine has published a new expert consensus statement affirming evidence-based lifestyle interventions as foundational, primary, and adjunctive treatments for major ...

J&J presented the new analysis from three Phase III trials of Caplyta in MDD.

Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical ...

The FDA clears ProlivRx at-home neuromodulation for adjunctive major depressive disorder treatment in adults with inadequate antidepressant response.

OMAHA, Neb. (WOWT) - Major depressive disorder is one of the most common psychiatric disorders in the world. It can affect a person’s thoughts, feelings and actions. Nearly 22 million adults in ...

Adjunctive omega-3 therapy failed to improve moderate-to-severe depression more than place ...

Remission (MADRS total score ≤10) was seen in 65% of patients treated with lumateperone in combination with an oral antidepressant, at 6 months. The Food and Drug Administration (FDA) has approved ...

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...

This approval represents a significant regulatory milestone, making Proliv™Rx the first and only at-home neuromodulation ...